

Medical Policy: Portrazza® (necitumumab)

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.159	January 16, 2024	

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Portrazza (necitumumab): is a recombinant IgG EGFR monoclonal antibody which binds to the ligand binding site of the EGFR receptor to prevent receptor activation and downstream signaling. **Portrazza** is FDA approved in combination with gemcitabine and cisplatin for first-line treatment of people with metastatic squamous non-small cell lung cancer (NSCLC).

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

Dosing Limits [Medical Benefit]

Max Units (per dose and over time):

- 800 billable units Day 1 and 8 every 21 days

Guideline

I. INITIAL APPROVAL CRITERIA

Portrazza may be considered medically necessary if one of the below conditions are met **AND** use is consistent with the medical necessity criteria that follows:

1. **Non-Small Cell Lung Cancer (NSCLC)**

- A. The member has metastatic NSCLC and Portrazza (necitumumab) is being used in combination with gemcitabine and cisplatin; **AND**
- B. The member's disease has squamous cell histology

Limitations/Exclusions

Portrazza is not considered medically necessary for when any of the following selection criteria is met:

- 1. Disease progression while taking Portrazza.
- 2. Dosing exceeds single dose limit of 800 mg.
- 3. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature may be deemed as not approvable and therefore not reimbursable.

II. RENEWAL CRITERIA

- 1. Patient continues to meet INITIAL APPROVAL CRITERIA.
- 2. Tumor response with disease stabilization or reduction of tumor size and spread.

Dosage/Administration

Indication	Dose
Squamous NSCLC	800 mg IV Days 1 and 8 of each 3-week cycle prior to gemcitabine and cisplatin infusion.

Applicable Procedure Codes

Code	Description
J9295	Injection, necitumumab, 1 mg, 1 billable unit = 1 mg

Applicable NDCs

Code	Description
00002-7716-xx	Portrazza 800 mg/50 mL vial

ICD-10 Diagnoses

Code	Description
C33	Malignant neoplasm of trachea
C34.00	Malignant neoplasm of unspecified main bronchus
C34.01	Malignant neoplasm of right main bronchus
C34.02	Malignant neoplasm of left main bronchus
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung

C34.11	Malignant neoplasm of upper lobe, right bronchus or lung
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung
Z85.118	Personal history of other malignant neoplasm of bronchus and lung

Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	1/16/2024	Annual Review: No criteria changes
EmblemHealth & ConnectiCare	5/19/2023	Annual Review: Initial Criteria: NSCLC: removed "The member has recurrent or metastatic NSCLC and Portrazza (necitumumab) is being used in combination with gemcitabine and cisplatin as ONE of the following: i. First line therapy ii. Subsequent therapy for sensitizing EGFR mutation-positive tumors AND prior erlotinib, afatinib, or gefitinib therapy, Subsequent therapy for ALK positive tumors AND prior crizotinib therapy" Added: "The member's disease has squamous cell histology"
EmblemHealth & ConnectiCare	09/26/2022	Transferred policy to new template
EmblemHealth & ConnectiCare	07/15/2019	Annual review

References

1. PI prescribing information accessed on 3/22/16:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
2. Clinical Pharmacology Elsevier Gold Standard. 2016.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2016.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2016
5. AHFS Drug Information. American Society of Health-Systems Pharmacists. Bethesda, MD. 2016.
6. Lexicomp Online®, Pediatric & Neonatal Lexi-Drugs®, Hudson, Ohio: Lexi-Comp, Inc. 2016.